Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM versus TRIVARIS.
CARDIZEM vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium influx into cardiac and vascular smooth muscle cells during depolarization by binding to L-type calcium channels. This results in coronary vasodilation, decreased myocardial oxygen demand, and negative chronotropic and inotropic effects.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
Oral: 30-120 mg three to four times daily; extended-release: 120-360 mg once daily. IV: Initial 0.25 mg/kg (max 25 mg) bolus over 2 minutes, may repeat in 15 minutes (0.35 mg/kg); maintenance: 5-15 mg/hour continuous infusion.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 3.0-4.5 hours in healthy adults; may be prolonged to 7-9 hours in elderly, hepatic impairment, or renal impairment; clinically relevant for dosing frequency.
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Primarily hepatic metabolism with extensive first-pass effect; approximately 2-4% excreted unchanged in urine; fecal excretion accounts for about 65% of dose as metabolites; renal excretion accounts for about 35% of dose as metabolites.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Calcium Channel Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination